PATHKEY.AI LTD (ASX: PKY)
Information technology · News and insights
Price unavailable
Latest PKY announcements
Announcement Insights
Pathkey.AI Advances Chipforge Toward Release As TrialKey Secures First Contracted Project
Pathkey.AI has moved both products closer to commercial work: Chipforge secured a first proof-of-value contract in October and was independently shown in November to turn written requirements into working FPGA hardware, with a broader release targeted for early 2027. TrialKey also converted its offering into contracted project work through a Paradigm agreement, although the approximately $25,000 engagement is an assessment of a Phase 3 trial that missed its interim threshold, and its outcome remains unchanged. A completed $2.8 million placement helped fund product development and commercialisation; cash was $5.83 million with no debt at quarter-end.
Updated 10 Nov 2026, 10:37 PM Sydney time
Sources
PKY Secures Paradigm Contract & Expands Trial Capabilities2026 AGM Presentation2026 Investor Webinar Recording AccessResults of MeetingAdoption of New ConstitutionIndependent Verification of Platform beyond design intentChange of AddressQuarterly Activities & Cashflow ReportComments
2026-11-10 · Information technology
PKY: $0.015 -6.25% · MC: $20M
Pathkey.AI says its TrialKey subsidiary has signed a services agreement with Paradigm Biopharmaceuticals, which is in voluntary administration, to independently assess whether trial design, conduct or analysis could have affected the interim result of Paradigm’s Phase 3 osteoarthritis study; the study did not meet its pre-set threshold to continue, and the outcome remains unchanged. The contract is valued at approximately $25,000 plus GST, and Pathkey says the work turns TrialKey’s broader offering into contracted project work. Internal retrospective testing also showed improved predictive performance, while further capabilities remain under testing or client validation.
Updated 2026-11-10 09:42
Sources
PKY Secures Paradigm Contract & Expands Trial CapabilitiesComments
2026-11-05 · Information technology
PKY: $0.015 +0.00% · MC: $20M
Pathkey.AI says Chipforge has been independently tested from written requirements to working FPGA hardware without help from its team, and is targeting a broader product release in early 2027. Shareholders carried all AGM resolutions, including ratification of prior share issues and approval of a placement facility. The company also made its investor webinar recording available, outlining commercialisation priorities for Chipforge and TrialKey.
Updated 2026-11-05 15:43
Sources
2026 AGM Presentation2026 Investor Webinar Recording AccessResults of MeetingAdoption of New ConstitutionComments
2026-11-04 · Information technology
PKY: $0.015 -6.25% · MC: $20M
An independent expert used Pathkey.AI’s Chipforge platform to produce working FPGA hardware from written requirements without help from the company team or manual code edits. The company also reports internal benchmark results 14 to 28 percentage points above published results for GPT-5, Claude 4 Sonnet and the MAGE research agent on the same tasks; the broader Chipforge Studio release is targeted for the first quarter of 2027.
Updated 2026-11-04 10:01
Sources
Independent Verification of Platform beyond design intentComments
2026-10-30 · Information technology
PKY: $0.016 +0.00% · MC: $20M
Pathkey.AI says Chipforge secured its first customer contract ahead of platform release, while a completed $2.8 million placement supported product development and commercialisation; cash stood at $5.83 million with no debt at quarter-end. The company reports increased TrialKey business-development activity and anticipates new client engagement in the December quarter, while Chipforge development continues toward commercial release. The contract is a proof-of-value project, and the company says recurring revenue will depend on customer adoption.
Updated 2026-10-30 20:18
Sources
Quarterly Activities & Cashflow ReportChange of AddressComments
Comments